Streetbeat News

Regulatory

ALNY

Alnylam Pharmaceuticals presented new data from the HELIOS-B Phase 3 study of vutrisiran, showing its potential as a first-line therapy for ATTR amyloidosis with cardiomyopathy. The data demonstrated significant improvements in cardiac biomarkers and echocardiographic parameters, indicating a disease-modifying effect. Alnylam plans to complete global regulatory submissions by the end of the year.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 7:05 am

MESO

Mesoblast Limited has secured a $50 million convertible note deal with its largest shareholder, contingent on FDA approval of its product Ryoncil for treating SR-aGvHD in children. The funding will support the company's commercial launch strategy.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 6:54 am

VRNA

Verona Pharma will present results from its Phase 3 ENHANCE studies on Ohtuvayre, a novel COPD treatment, at the CHEST 2024 meeting. The studies show Ohtuvayre's efficacy in improving lung function and reducing exacerbations in COPD patients.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 6:44 am

CME

CME Group is set to launch Spodumene CIF China Futures on October 28, 2024, expanding its battery metals suite. This move aims to enhance hedging capabilities in the lithium value chain, with support from industry players like Albemarle and Liontown.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 6:42 am

BYDDF

BYDDY

BYD is recalling nearly 97,000 EVs due to overheating risks in the CEPS system, potentially causing fires. The recall affects Dolphin and Yuan PLUS models produced between November 2022 and December 2023. BYD will fix the issue at no cost to customers.

Portfolio Pulse from Anan Ashraf

September 30, 2024 | 6:17 am

SOLUSD

A cryptocurrency analyst predicts a 5x surge for Solana (SOL) by Q4 2025, citing its strong DeFi adoption and potential to lead a blockchain revolution. However, regulatory concerns from the SEC could impact its growth.

Portfolio Pulse from Aniket Verma

September 30, 2024 | 5:57 am

BTCUSD

El Salvador is increasing Bitcoin's visibility by displaying its price on digital screens in busy intersections, aiming to mainstream the cryptocurrency. Despite efforts, Bitcoin's adoption as legal tender hasn't met expectations.

Portfolio Pulse from Aniket Verma

September 30, 2024 | 3:20 am

BTCUSD

DOGEUSD

ETHUSD

Leading cryptocurrencies like Bitcoin and Ethereum traded flat ahead of Federal Reserve Chair Jerome Powell's speech, while Dogecoin saw a decline. Bitcoin's recent rally was driven by a central bank rate cut, and analysts predict a long-term bullish target for Bitcoin between $194K and $352K. The market sentiment remains one of 'Greed'.

Portfolio Pulse from Aniket Verma

September 30, 2024 | 1:58 am

GOOG

GOOGL

META

California Governor Gavin Newsom vetoed a bill aimed at regulating AI, backed by Elon Musk, due to concerns it could stifle innovation. Major tech companies like Google, OpenAI, and Meta opposed the bill, fearing it would hinder AI development.

Portfolio Pulse from Ananya Gairola

September 30, 2024 | 1:39 am

GS

US stocks have shown resilience amid economic volatility, with the S&P 500 Index achieving significant gains and crossing a $50 trillion market cap. Despite potential recession threats, optimism remains, supported by increased bets on tech stocks by Goldman Sachs. Key upcoming events include jobs reports, earnings, the US presidential election, and the Fed's interest-rate decision.

Portfolio Pulse from Bibhu Pattnaik

September 29, 2024 | 7:30 pm